

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PANTHERIX LIMITED	06/02/2006
RECEIVING PARTY DATA	
Name:	BASILEA PHARMACEUTICA AG
Street Address:	Grenzacherstrasse 487
City:	CH 4058 Basel
State/Country:	SWITZERLAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6916803
CORRESPONDENCE DATA	
Fax Number:	(352)372-5800
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	3523758100
Email:	drs@slspatents.com
Correspondent Name:	DAVID R. SALIWANCHIK
Address Line 1:	P.O. BOX 142950
Address Line 4:	GAINESVILLE, FLORIDA 32614-2950
ATTORNEY DOCKET NUMBER:	GJE-7176
NAME OF SUBMITTER:	DAVID R. SALIWANCHIK
Total Attachments: 5 source=ASGN.Basilea#page1.tif source=ASGN.Basilea#page2.tif source=ASGN.Basilea#page3.tif source=ASGN.Basilea#page4.tif source=ASGN.Basilea#page5.tif	

CH \$40.00 6916803

GLOBAL PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT is made on ^{2 June}~~31st May~~ 2006

BETWEEN

- (1) **PANTHERIX LIMITED**, a company incorporated in England and Wales under the Companies Act (number 3464985) and having its registered office at c/o Merlin Biosciences Limited, 33 King Street, St. James's, London, SW1Y 6RJ (the "**Assignor**"); and
- (2) **BASILEA PHARMACEUTICA AG**, a company incorporated in Switzerland and having its registered office at Grenzacherstrasse 487, CH 4058 Basel, Switzerland (the "**Assignee**").

THE PARTIES AGREE as follows:

1. DEFINITIONS

In this Assignment:

"**Asset Purchase Agreement**" means the asset purchase agreement dated 24th April 2006 and made between the Assignor and the Assignee under which the Assignor agreed to assign the Patents to the Assignee; and

"**Patents**" means together the registered patents and patent applications listed in the schedule to this Assignment.

2. ASSIGNMENT

2.1 Pursuant to the Asset Purchase Agreement (and for the consideration contained therein), the Assignor hereby sells, assigns and transfers to the Assignee absolutely with full title guarantee:

2.1.1 all its right, title and interest in and to the Patents and all legal rights and immunities (howsoever derived) attaching thereto in each case and free from any claim, option, charge, lien, equity, encumbrance, right of pre-emption or any other third party right and including (without limitation):

- (a) the right to sue for and to recover damages and other remedies in respect of any infringement of any of the Patents or any other acts

carried out by another person within the scope of the claims of any of the Patents which may have occurred before the date of this Assignment; and

- (b) the right to apply for, prosecute and obtain patent protection or similar rights throughout the world in respect of any of the inventions claimed in the Patents including the right to claim priority therefrom to the intent that the grant of letters patent or similar protection shall be in the name of and vest in the Assignee.

3. **NOT CUMULATIVE**

For the avoidance of doubt, any liability of the Assignor under this Agreement (including, without limitation, any liability in respect of a breach of this Assignment) is not cumulative with any liability that the Assignor has under the Asset Purchase Agreement. The Assignee may recover only once for the same loss.

4. **GOVERNING LAW**

This Assignment is governed by the laws of England and Wales.

SCHEDULE: THE PATENTS

Part 1: Granted patents

Title	Country	Application no.	Earliest Priority date	Application date	Publication no.	Publication date	Patent no.	Grant date
3- (Heteroaryl)acetamido)-2-oxo-azetidone-1-sulfonic acids derivatives as antibacterial agents	China	01815731.9	14-Sep-2000	14.09.2001	CN 1458932	26/11/2003	195237	16.02.2005
	Europe	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Austria	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Belgium	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Cyprus	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Denmark	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Finland	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	France	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Germany	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Greece	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Ireland	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Italy	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Lithuania	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Luxembourg	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Monaco	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Netherlands	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Portugal	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Spain	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Sweden	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Switzerland	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	Turkey	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	United Kingdom	01980829.4	14-Sep-2000	14.09.2001	EP 1322648		1322648	29.06.2005
	New Zealand	524292	14-Sep-2000	14.09.2001	NZ524292	24/09/2004	524292	13.01.2005
South Africa	2003/2085	14-Sep-2000	14.09.2001	ZA200302085	15/03/2004	2003/2085	26.05.2004	
USA	10/363222	14-Sep-2000	14.09.2001	US2004019203	29/01/2004	6916803	12.07.2005	

Part 2: Patent applications

Title	Country	Application no.	Earliest Priority date	Application date	Publication no.	Publication date
3- (Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents	Australia	2002212614	14-Sep-2000	14.09.2001	AU1261402	26/03/2002
	Brazil	PI 0113861-8	14-Sep-2000	14.09.2001	BR0113861	27/01/2004
	Canada	2422375	14-Sep-2000	14.09.2001	CA 2422375	21/03/2002
	Czech Republic	PV 2003-606	14-Sep-2000	14.09.2001	CZ 2003000606	13/08/2003
	Hong Kong	03106287.6	14-Sep-2000	14.09.2001	HK1054377	03/02/2006
	Hungary	HU20030001025	14-Sep-2000	14.09.2001	HU 0301025	28/04/2004
	Indonesia	W-00200300737	14-Sep-2000	14.09.2001		
	Israel	154593	14-Sep-2000	14.09.2001	IL 154593	
	Japan	2002-526866	14-Sep-2000	14.09.2001	JP2004509122	25/03/2005
	Korea (Republic of)	2003-7003718	14-Sep-2000	14.09.2001	KR 2003039369	
	Norway	2003 1162	14-Sep-2000	14.09.2001	NO20031162	13/03/2003
	Philippines	1-2003-500044	14-Sep-2000	14.09.2001		
	Poland	P360537	14-Sep-2000	14.09.2001	PL360537	06/09/2004
	Slovak Republic	PV 0246-2003	14-Sep-2000	14.09.2001	SK2462003	11/09/2003
United States Patent Application International patent application		60/232,617	14-Sep-2000	14.09.2000		
		PCT/IB01/02115	14-Sep-2000	14.09.2001	WO0222613	21/03/2002

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives.

U. Eisenring
Signed by ~~Dr. Anthony Man, CEO~~

U. Eisenring

For and on behalf of Basilea Pharmaceutica AG

Signed by ~~Ron Scott, CEO~~ *D. Spota*
D. Spota

For and on behalf of Basilea Pharmaceutica AG

Visum Legal, Basilea Pharmaceutica AG *UE*

Ulrich Eisenring

2 June
Date: ~~31st May~~ 2006

Signed by Alexander McDougall

Alexander McDougall

For and on behalf of Atlantic Corrie Limited
Company Secretary to PanTherix Limited

2 June
Date: ~~31st May~~ 2006